Giusti et al. disclosed that HER2 loss also results in both trastuzumab resistance and enhanced stemness of breast cancer34, which is consistent with our findings and indicates HER2 loss probably is likely to correlated LINC00589. However, LINC00589 is unlikely to regulate HER2 expression in breast cancer and instead exerts multiple functions in trastuzumab resistance, MDR and CSC-like properties through a HER2-independent mechanism. This evidence concerns the gene ERBB2 and breast carcinoma.